US3789119A - Stabilized molded sublingual nitroglycerin tablets - Google Patents

Stabilized molded sublingual nitroglycerin tablets Download PDF

Info

Publication number
US3789119A
US3789119A US00149072A US3789119DA US3789119A US 3789119 A US3789119 A US 3789119A US 00149072 A US00149072 A US 00149072A US 3789119D A US3789119D A US 3789119DA US 3789119 A US3789119 A US 3789119A
Authority
US
United States
Prior art keywords
nitroglycerin
tablets
solvent
water
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00149072A
Inventor
S Fusari
L Lueck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parke Davis and Co LLC
Original Assignee
Parke Davis and Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parke Davis and Co LLC filed Critical Parke Davis and Co LLC
Application granted granted Critical
Publication of US3789119A publication Critical patent/US3789119A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • compositions in the form of tablets suitable for sublingual administration, can be produced by wetting a substantially dry mixture of the nitroglycerin and the solid, water-soluble pharmaceutical carrier with a solvent mixture containing a non-volatile, water-soluble solvent and a volatile solvent, forming the wetted mixture into tablets, and removing the volatile solvent.
  • the present invention relates to new and improved pharmaceutical compositions of nitroglycerin, and to methods for producing those compositions.
  • Nitroglycerin (glyceryl trinitrate) is widely used in medical practice as a coronary vasodilator. It is normally used in the form of tablets for sublingual administration containing approximately 0.2 to 0.65 mg. of nitroglycerin per tablet. Nitroglycerin tablets are administered for the purpose of producing a rapid coronary vasodilator effect relieving acute attacks of angina pectoris, and thus it is important that they retain the correct potency in terms of the active ingredient and that the active ingredient be promptly released for absorption upon sublingual administration.
  • nitroglycerin tablets that meet accepted standards of potency and uniformity at the time of manufacture may fail to meet those standards of potency and uniformity following storage over a period of only a few months or less.
  • nitroglycerin tablets it has been found that the failure of nitroglycerin tablets to maintain satisfactory potency and uniformity upon storage can be attributed to a migration of nitroglycerin from tablet to tablet and from the tablets to the environment. It has been found that the migration of nitroglycerin from the tablets to the environment is especially significant when the container is not tightly sealed so that the nitroglycerin can volatilize from the tablets through the loose seal into the atmosphere. It has also been found that the migration of nitroglycerin from the tablets to the environment is especially significant when the container has rayon or cotton stuffing material whereby nitroglycerin is volatilized from the tablets and absorbed on the stuffing material.
  • Another object of the invention is to provide pharmaceutical formulations of nitroglycerin in the form of sublingual tablets whichdo not undergo a significant degree of migration of nitroglycerin from tablet to tablet within the same container.
  • a further object of the invention is to provide pharmaceutical formulations of nitroglycerin in the form of sublingual tablets which retain their original potency without significant deviation over a long period of storage.
  • Still a further object of the invention is to provide pharmaceutical formulations of nitroglycerin in the form of sublingual tablets having the improved potency retention mentioned above and having in addition the cal compositions of nitroglycerin are prepared to contain in finished form (a) one part by weight of nitroglycerin, in combination with (b) 0.1 to 4 parts by weight of a non-volatile, water-soluble solvent, and (c) 20 to 200 parts by weight of a solid, water-soluble pharmaceutical carrier.
  • non-volatile is used herein in a relative. sense to designate a solvent that when incorporated in the finished formulation volatilizes to no more than a minor extent over a period'of several months at ordinary temperatures and under ordinary conditions of storage.
  • That solvent can be a high boiling liquid or a high boiling, low melting solid that exhibits the required solvent characteristics under the conditions of use. It should have a relatively high solubility for nitroglycerin.
  • Some examples of such solvents are polyethylene glycols, tetramethylene glycol, and pentamethylene glycol.
  • Preferred solvents are polyethylene glycols having an average molecular weight in the range of 300 to 7,500, especially 300 to 1,000.
  • a preferred ratio of ingredients is one part by weight of nitroglycerin to 0.5 to 0.9 parts by weight of the nonvolatile, water-soluble solvent.
  • the solid, water-soluble pharmaceutical carrier is a sugar or a sugar derivative such as lactose, glucose, sucrose, mannitol, or sorbitol.
  • the solid, water-soluble pharmaceutical carrier is used in an amount, within the proportions indicated above, to impart to the finished formulation the desired solid state under normal as well as extreme temperature conditions of storage and use.
  • the new pharmaceutical formulations of nitroglycerin, as described above, are desirably provided as tablets suitable for sublingual administration and containing 0.l to 1.0 mg, preferably 0.2 to 0.65 mg., of nitroglycerin per tablet. However, if desired, they can also be provided in other conventional pharmaceutical forms such as granules.
  • compositions of nitroglycerin in the form of tablets for sublingual administration are produced by the process which comprises (a) preparing a substantially dry mixture of one part by weight of nitroglycerin and 20 i to 200 parts by weight of a solid, water-soluble pharmaceutical carrier, (b) wetting that substantially dry mixture with a solvent mixture containing 0.1 to 4 parts by weight of a non-volatile, water-soluble solvent and a sufficient quantity of a volatile solvent to permit an even wetting of the substantially dry mixture by the solvent mixture, (c) forming the wetted mixture into tab-- lets, and (d) drying the tablets whereby substantially all of the volatile solvent is volatilized while substantially all of the non-volatile solvent remains unvolatilized.
  • non-volatile is used herein in a relative sense to designate a solvent that when incorporated in the finished formulation volatilizes to no more than a minor extent over a period of several months at ordinary temperatures and under ordinary conditions of storage.
  • That solvent can be a high boiling liquid or a high boiling, low melting solid that exhibits the required solvent characteristics under the conditions of use. It should have a relatively high solubility for nitroglycerin.
  • Some examples of such solvents are polyethylene glycols, tetramethylene glycol, and pentamethylene glycol.
  • Preferred solvents are polyethylene glycols having an average molecular weight in the range of 300 to 7,500, especially 300 to 1,000.
  • a preferred ratio of ingredients is one part by weight of nitroglycerin to 0.5 to 0.9 parts by weight of the non-volatile, water-soluble solvent.
  • volatile is used herein in a relative sense to designate a solvent that readily volatilizes under the conditions normally used in drying pharmaceutical tablets, for example drying in air at room temperature for 12 to 48 hours.
  • solvents most suitably have a boiling point of about 100 C. or lower and a preferred solvent for this purpose is aqueous ethanol or water.
  • the solid, water-soluble pharmaceutical carrier is a sugar or a sugar derivative such as lactose, glucose, sucrose, mannitol, or sorbitol.
  • the solid, water-soluble pharmaceutical carrier is used in an amount, within the proportions indicated above, to impart to the finished tablets the desired solid state under normal as well as extreme temperature conditions of storage and use.
  • the tablets, as prepared above, are desirably constituted to contain 0.1 to 1.0 mg., preferably 0.2 to 0.65 mg. of nitroglycerin per tablet.
  • compositions described above can, if desired, also be formulated to contain other ingredients useful in pharmaceutical compounding.
  • compositions of the invention exhibit the well-known activity of nitroglycerin in medical practice but show improved behavior on storage.
  • the sublingual tablets give a rapid coronary vasodilator effect when dissolved under the tongue.
  • they show improved retention of potency and uniformity when stored in either glass or plastic containers, with or without stuffing materials, at temperatures from room temperature to 45 C., when compared with the behavior of tablets prepared similarly but without the inclusion of a non-volatile, water soluble solvent.
  • EXAMPLE 1 Ingredient Quantity N trqs ysstin m xtu e p 10% nitroglycerin Dilugent (lactose sucrose. 44- 7 kg. 95:5) Solvent mixture containing: Ethanol. 95% 3381 ml. Polyethylene glycol 400 520 ml. Purified Water 1302 ml.
  • the nitroglycerin mixture soluble is a product containing 10% nitroglycerin on ,B-lactose and the quantity used is seven percent in excess of the calculated amount.
  • the diluent contains 95% by weight of the usual lactose of pharmacy (at-lactose monohydrate) and 5% by weight of sucrose.
  • the polyethylene glycol 400 is a polymer of ethylene oxide and water, represented by the formula H(OCH CH ),,OH, in which the average value ofn lies between 8.2 and 9.1.
  • the nitroglycerin mixture soluble is blended with a sufficient quantity of diluent to produce a siftable mixture.
  • the siftable mixture is passed through a number 80 mesh silk sieve.
  • Approximately one-half of the diluent, then the sifted nitroglycerin and diluent mixture, and then the remainder of the diluent are added to a blender and thoroughly mixed. While the blender is operating the solvent mixture is then added and the ingredients are again blended.
  • the wetted mixture is then formed into tablets, each weighing approximately 34 mg. after air drying, on a tablet molding machine.
  • Optimum temperature and humidity conditions for this operation are a dry bulb temperature of 22 to 26 C. and a dew point temperature of 6 to 9 C.
  • the molded tablets are collected into trays and air dried at room temperature. Yield equals 1,400,000 to 1,500,000 tablets, each weighing approximately 34 mg. and labeled to contain l/150 grain (approximately 0.43 mg.) of nitroglycerin per tablet; the acceptable variation is an average assay of percent to l 1 percent of the indicated potency.
  • the tablets prepared as described above are suitable for sublingual administration and exhibit improved behavior on storage when compared with tablets prepared similarly but without the use of polyethylene glycol. They maintain acceptable standards of potency and uniformity upon prolonged storage at room temperature, at 37 C., and at 45 C.
  • the improved behav ior on storage is observed in closed containers as well as in containers that are opened periodically to simulate conditions of use. i
  • EXAMPLE 2 Ingredient Quantity l lit 'oglycerin mixture soluble, 10.2 kg. 10% nitroglycerin Diluent (lactose sucrose. 40.8 k :5)
  • the nitroglycerin mixture soluble is a product containing 10% nitroglycerin on B-lactose and the quantity used is five percent in excess of the calculated amount.
  • the diluent contains 95% by weight of the usual lactose of pharmacy (ct-lactose monohydrate) and 5% by weight of sucrose.
  • the polyethylene glycol 400 is a polymer of ethylene oxide and water, represented by the formula H(OCH CH ),,OH, in which the average value of n lies between 8.2 and 9.1.
  • the nitroglycerin mixture soluble is blended with a sufficient quantity of diluent to produce a siftable mixture.
  • the siftable mixture is passed through a number 80 mesh silk sieve.
  • Approximately one-half of the diluent, then the sifted nitroglycerin and diluent mixture, and then the remainder of the diluent are added to a blender and thoroughly mixed; While the blender is operating the solvent mixture is then added and the ingredients are again blended.
  • the wetted mixture is then formed into tablets, each weighing approxi mately 34 mg. after air drying, on a tablet molding machine.
  • Optimum temperature and humidity conditions for this operation are a dry bulb-temperature of 22 to 26 C.
  • the nitroglycerin mixture soluble is a product containing 10% nitroglycerin on B-lactose and the quantity used is nine percent in excess of the calculated amount.
  • the diluent contains 95% by weight of the usual lactose of pharmacy (oz-lactose monohydrate) and 5% by weight of sucrose.
  • the polyethylene glycol 400 is a polymer of ethylene and water, represented by the formula H(OCH CH ),,OH, in which the average value of n lies bemately 34 mg. after air drying, on a tablet molding machine.
  • Optimum temperature and humidity conditions for this operation are a dry bulb temperature of 22 to 26 C. and a dew point temperature of 6 to 9 C.
  • the molded tablets are collected into trays and air dried at room temperature. Yield equals 1,400,000 to 1,500,000 tablets, each weighing approximately 34 mg.
  • the tablets prepared as described above are suitable for sublingual administration and exhibit improved behavior on storage as described in Example 1.
  • a pharmaceutical molded tablet composition for sublingual administration consisting essentially of a. one part by weight of nitroglycerin,
  • a non-volatile, watersoluble solvent selected from the group consisting of polyethylene glycols having an average molecular weight in the range of 300 to 7,500, tetramethylene glycol, and pentamethylene glycol, and
  • said molded sublingual tablet composition being capable of giving a rapid release of nitroglycerin upon sublingual administration, and being thereby stabilized against the tendency of nitroglycerin to otherwise migrate significantly from tablet to tablet, from tablet to environment, and from tablet 'to container stuffing capable of absorbing nitroglycerin in sealed or imperfectly sealed containers with resulting loss of original potency during storage.
  • non-volatile, water-soluble solvent is a polyethylene glycol having an average molecular weight of 300 to 1,000.
  • a pharmaceutical composition according to claim 1 wherein the solid, water-soluble pharmaceutical carrier is substantially a mixture of lactose and sucrose.

Abstract

Pharmaceutical compositions containing minor proportions of nitroglycerin and a non-volatile, water-soluble solvent in combination with a major proportion of a solid, water-soluble pharmaceutical carrier. Those compositions, in the form of tablets suitable for sublingual administration, can be produced by wetting a substantially dry mixture of the nitroglycerin and the solid, water-soluble pharmaceutical carrier with a solvent mixture containing a non-volatile, water-soluble solvent and a volatile solvent, forming the wetted mixture into tablets, and removing the volatile solvent.

Description

United States Patent [191 Fusari et al.
[ Jan. 29, 1974 STABILIZED MOLDED SUBLINGUAL NITROGLYCERIN TABLETS [75] Inventors: Salvatore A. Fusari, St. Clair Shores; Leslie M. Lueck, Oxford,
211 Appl. No.: 149,072
[52] US. Cl 424/78, 264/117, 424/298,
Preckel 424/349 X OTHER PUBLICATIONS Stephenson et al., J. Pharm. Pharma Col(3): 767-776 (195]) Tablets of Glycoryl Trinitrate Primary Examiner-Shep K. Rose Attorney, Agent, or Firm-Robert R. Adams; David B. Ehrlinger; George M. Richards; Edward .I. Gall [5 7] ABSTRACT Pharmaceutical compositions containing minor proportions of nitroglycerin and a non-volatile, watersoluble solvent in combination with a major proportion of a solid, water-soluble pharmaceutical carrier. Those compositions, in the form of tablets suitable for sublingual administration, can be produced by wetting a substantially dry mixture of the nitroglycerin and the solid, water-soluble pharmaceutical carrier with a solvent mixture containing a non-volatile, water-soluble solvent and a volatile solvent, forming the wetted mixture into tablets, and removing the volatile solvent.
4 Claims, N0 Drawings STABILIZED MQLDED SUBLINGUAL NITROGLYCERIN TABLETS SUMMARY AND DETAILED DESCRIPTION The present invention relates to new and improved pharmaceutical compositions of nitroglycerin, and to methods for producing those compositions.
Nitroglycerin (glyceryl trinitrate) is widely used in medical practice as a coronary vasodilator. It is normally used in the form of tablets for sublingual administration containing approximately 0.2 to 0.65 mg. of nitroglycerin per tablet. Nitroglycerin tablets are administered for the purpose of producing a rapid coronary vasodilator effect relieving acute attacks of angina pectoris, and thus it is important that they retain the correct potency in terms of the active ingredient and that the active ingredient be promptly released for absorption upon sublingual administration.
It is known that nitroglycerin tablets that meet accepted standards of potency and uniformity at the time of manufacture may fail to meet those standards of potency and uniformity following storage over a period of only a few months or less.
In accordance with the present invention, it has been found that the failure of nitroglycerin tablets to maintain satisfactory potency and uniformity upon storage can be attributed to a migration of nitroglycerin from tablet to tablet and from the tablets to the environment. It has been found that the migration of nitroglycerin from the tablets to the environment is especially significant when the container is not tightly sealed so that the nitroglycerin can volatilize from the tablets through the loose seal into the atmosphere. It has also been found that the migration of nitroglycerin from the tablets to the environment is especially significant when the container has rayon or cotton stuffing material whereby nitroglycerin is volatilized from the tablets and absorbed on the stuffing material. However, in accordance with the invention, migration of nitroglycerin from tablet to tablet with resulting loss of uniformity has been found to occur even in sealed glass containers without rayon or cotton stuffing material. The lack of uniformity can be demonstrated by the fact that after storage some tablets have abnormally high potency and some tablets have abnormally low potency, even though the average potency may remain within acceptable limits.
It is an object of the present invention to provide pharmaceutical formulations of nitroglycerin that retain an acceptable level of potency even in an imperfectly sealed container and in the presence of rayon, cotton, or other material capable of absorbing nitroglycerin.
Another object of the invention is to provide pharmaceutical formulations of nitroglycerin in the form of sublingual tablets whichdo not undergo a significant degree of migration of nitroglycerin from tablet to tablet within the same container.
A further object of the invention is to provide pharmaceutical formulations of nitroglycerin in the form of sublingual tablets which retain their original potency without significant deviation over a long period of storage.
Still a further object of the invention is to provide pharmaceutical formulations of nitroglycerin in the form of sublingual tablets having the improved potency retention mentioned above and having in addition the cal compositions of nitroglycerin are prepared to contain in finished form (a) one part by weight of nitroglycerin, in combination with (b) 0.1 to 4 parts by weight of a non-volatile, water-soluble solvent, and (c) 20 to 200 parts by weight of a solid, water-soluble pharmaceutical carrier. The term non-volatile is used herein in a relative. sense to designate a solvent that when incorporated in the finished formulation volatilizes to no more than a minor extent over a period'of several months at ordinary temperatures and under ordinary conditions of storage. That solvent can be a high boiling liquid or a high boiling, low melting solid that exhibits the required solvent characteristics under the conditions of use. It should have a relatively high solubility for nitroglycerin. Some examples of such solvents are polyethylene glycols, tetramethylene glycol, and pentamethylene glycol. Preferred solvents are polyethylene glycols having an average molecular weight in the range of 300 to 7,500, especially 300 to 1,000. A preferred ratio of ingredients is one part by weight of nitroglycerin to 0.5 to 0.9 parts by weight of the nonvolatile, water-soluble solvent. The solid, water-soluble pharmaceutical carrier is a sugar or a sugar derivative such as lactose, glucose, sucrose, mannitol, or sorbitol. The solid, water-soluble pharmaceutical carrier is used in an amount, within the proportions indicated above, to impart to the finished formulation the desired solid state under normal as well as extreme temperature conditions of storage and use. The new pharmaceutical formulations of nitroglycerin, as described above, are desirably provided as tablets suitable for sublingual administration and containing 0.l to 1.0 mg, preferably 0.2 to 0.65 mg., of nitroglycerin per tablet. However, if desired, they can also be provided in other conventional pharmaceutical forms such as granules.
Also in accordance with the invention, pharmaceutical compositions of nitroglycerin in the form of tablets for sublingual administration are produced by the process which comprises (a) preparing a substantially dry mixture of one part by weight of nitroglycerin and 20 i to 200 parts by weight of a solid, water-soluble pharmaceutical carrier, (b) wetting that substantially dry mixture with a solvent mixture containing 0.1 to 4 parts by weight of a non-volatile, water-soluble solvent and a sufficient quantity of a volatile solvent to permit an even wetting of the substantially dry mixture by the solvent mixture, (c) forming the wetted mixture into tab-- lets, and (d) drying the tablets whereby substantially all of the volatile solvent is volatilized while substantially all of the non-volatile solvent remains unvolatilized. The term non-volatile is used herein in a relative sense to designate a solvent that when incorporated in the finished formulation volatilizes to no more than a minor extent over a period of several months at ordinary temperatures and under ordinary conditions of storage. That solvent can be a high boiling liquid or a high boiling, low melting solid that exhibits the required solvent characteristics under the conditions of use. It should have a relatively high solubility for nitroglycerin. Some examples of such solvents are polyethylene glycols, tetramethylene glycol, and pentamethylene glycol. Preferred solvents are polyethylene glycols having an average molecular weight in the range of 300 to 7,500, especially 300 to 1,000. A preferred ratio of ingredients is one part by weight of nitroglycerin to 0.5 to 0.9 parts by weight of the non-volatile, water-soluble solvent. The term volatile is used herein in a relative sense to designate a solvent that readily volatilizes under the conditions normally used in drying pharmaceutical tablets, for example drying in air at room temperature for 12 to 48 hours. Such solvents most suitably have a boiling point of about 100 C. or lower and a preferred solvent for this purpose is aqueous ethanol or water. The solid, water-soluble pharmaceutical carrier is a sugar or a sugar derivative such as lactose, glucose, sucrose, mannitol, or sorbitol. The solid, water-soluble pharmaceutical carrier is used in an amount, within the proportions indicated above, to impart to the finished tablets the desired solid state under normal as well as extreme temperature conditions of storage and use. The tablets, as prepared above, are desirably constituted to contain 0.1 to 1.0 mg., preferably 0.2 to 0.65 mg. of nitroglycerin per tablet.
The pharmaceutical compositions described above can, if desired, also be formulated to contain other ingredients useful in pharmaceutical compounding.
The pharmaceutical compositions of the invention exhibit the well-known activity of nitroglycerin in medical practice but show improved behavior on storage. For example, the sublingual tablets give a rapid coronary vasodilator effect when dissolved under the tongue. Additionally, they show improved retention of potency and uniformity when stored in either glass or plastic containers, with or without stuffing materials, at temperatures from room temperature to 45 C., when compared with the behavior of tablets prepared similarly but without the inclusion of a non-volatile, water soluble solvent.
The invention is illustrated by the following examples.
EXAMPLE 1 Ingredient Quantity N trqs ysstin m xtu e p 10% nitroglycerin Dilugent (lactose sucrose. 44- 7 kg. 95:5) Solvent mixture containing: Ethanol. 95% 3381 ml. Polyethylene glycol 400 520 ml. Purified Water 1302 ml.
The nitroglycerin mixture soluble is a product containing 10% nitroglycerin on ,B-lactose and the quantity used is seven percent in excess of the calculated amount.
The diluent contains 95% by weight of the usual lactose of pharmacy (at-lactose monohydrate) and 5% by weight of sucrose.
The polyethylene glycol 400 is a polymer of ethylene oxide and water, represented by the formula H(OCH CH ),,OH, in which the average value ofn lies between 8.2 and 9.1.
The nitroglycerin mixture soluble is blended with a sufficient quantity of diluent to produce a siftable mixture. With care, the siftable mixture is passed through a number 80 mesh silk sieve. Approximately one-half of the diluent, then the sifted nitroglycerin and diluent mixture, and then the remainder of the diluent are added to a blender and thoroughly mixed. While the blender is operating the solvent mixture is then added and the ingredients are again blended. The wetted mixture is then formed into tablets, each weighing approximately 34 mg. after air drying, on a tablet molding machine. Optimum temperature and humidity conditions for this operation are a dry bulb temperature of 22 to 26 C. and a dew point temperature of 6 to 9 C. The molded tablets are collected into trays and air dried at room temperature. Yield equals 1,400,000 to 1,500,000 tablets, each weighing approximately 34 mg. and labeled to contain l/150 grain (approximately 0.43 mg.) of nitroglycerin per tablet; the acceptable variation is an average assay of percent to l 1 percent of the indicated potency.
The tablets prepared as described above are suitable for sublingual administration and exhibit improved behavior on storage when compared with tablets prepared similarly but without the use of polyethylene glycol. They maintain acceptable standards of potency and uniformity upon prolonged storage at room temperature, at 37 C., and at 45 C. The improved behav ior on storage is observed in closed containers as well as in containers that are opened periodically to simulate conditions of use. i
EXAMPLE 2' Ingredient Quantity l lit 'oglycerin mixture soluble, 10.2 kg. 10% nitroglycerin Diluent (lactose sucrose. 40.8 k :5)
Solvent mixture containing:
Ethanol 95% 3135 Polyethylene glycol 400 765 Purified water 1302 ml.
The nitroglycerin mixture soluble is a product containing 10% nitroglycerin on B-lactose and the quantity used is five percent in excess of the calculated amount.
The diluent contains 95% by weight of the usual lactose of pharmacy (ct-lactose monohydrate) and 5% by weight of sucrose.
The polyethylene glycol 400 is a polymer of ethylene oxide and water, represented by the formula H(OCH CH ),,OH, in which the average value of n lies between 8.2 and 9.1.
The nitroglycerin mixture soluble is blended with a sufficient quantity of diluent to produce a siftable mixture. With care, the siftable mixture is passed through a number 80 mesh silk sieve. Approximately one-half of the diluent, then the sifted nitroglycerin and diluent mixture, and then the remainder of the diluent are added to a blender and thoroughly mixed; While the blender is operating the solvent mixture is then added and the ingredients are again blended. The wetted mixture is then formed into tablets, each weighing approxi mately 34 mg. after air drying, on a tablet molding machine. Optimum temperature and humidity conditions for this operation are a dry bulb-temperature of 22 to 26 C. and a dew point temperature of 6 to 9 C. The molded tablets are collected into trays and air dried at oom temperature. Yield equals 1,400,000 to 1,500,000 tablets, each weighing approximately 34 mg. and labeled to contain 1/100 grain (approximately 0.65 mg.) of nitroglycerin per tablet; the acceptable variation is an average assay of 90 percent to percent of the indicated potency. I
. oxide The tablets prepared as described above are suitable for sublingual administration and exhibit improved behavior on storage as described in Example 1.
EXAMPLE 3 lngredient Quantity Nitroglycerin mixture soluble, 5.31 kg. nitroglycerin Diluem (lactose+sucrose. 45.69 kg. 95:5) Solvent mixture containing: Ethanol. 95% 3502 ml. BQDEIEYLQELE YWl 9. 398 Purified water 1302 ml. 7
The nitroglycerin mixture soluble is a product containing 10% nitroglycerin on B-lactose and the quantity used is nine percent in excess of the calculated amount.
The diluent contains 95% by weight of the usual lactose of pharmacy (oz-lactose monohydrate) and 5% by weight of sucrose.
The polyethylene glycol 400 is a polymer of ethylene and water, represented by the formula H(OCH CH ),,OH, in which the average value of n lies bemately 34 mg. after air drying, on a tablet molding machine. Optimum temperature and humidity conditions for this operation are a dry bulb temperature of 22 to 26 C. and a dew point temperature of 6 to 9 C. The molded tablets are collected into trays and air dried at room temperature. Yield equals 1,400,000 to 1,500,000 tablets, each weighing approximately 34 mg.
and labeled to contain 1/200 grain (approximately 0.32 mg.) of nitroglycerin per tablet; the acceptable variation is an average assay of percent to percent of the indicated potency.
The tablets prepared as described above are suitable for sublingual administration and exhibit improved behavior on storage as described in Example 1.
We claim:
1. A pharmaceutical molded tablet composition for sublingual administration consisting essentially of a. one part by weight of nitroglycerin,
b. 0.5 to 0.9 parts by weight of a non-volatile, watersoluble solvent selected from the group consisting of polyethylene glycols having an average molecular weight in the range of 300 to 7,500, tetramethylene glycol, and pentamethylene glycol, and
c. 20 to 200 parts by weight of a solid, water-soluble pharmaceutical carrierof the-class consisting of lactose, glucose, sucrose, niannitol, and sorbitol,
said molded sublingual tablet composition being capable of giving a rapid release of nitroglycerin upon sublingual administration, and being thereby stabilized against the tendency of nitroglycerin to otherwise migrate significantly from tablet to tablet, from tablet to environment, and from tablet 'to container stuffing capable of absorbing nitroglycerin in sealed or imperfectly sealed containers with resulting loss of original potency during storage.
2. A pharmaceutical composition according to claim 1 wherein the non-volatile, water-soluble solvent is a polyethylene glycol having an average molecular weight of 300 to 1,000.
3. A pharmaceutical composition according to claim 1 wherein the solid, water-soluble pharmaceutical carrier is substantially a mixture of lactose and sucrose.
4. A pharmaceutical composition according to claim 1 in the form of tablets containing-0.1 to 1.0 mg. of nitroglycerin per tablet.

Claims (3)

  1. 2. A pharmaceutical composition according to claim 1 wherein the non-volatile, water-soluble solvent is a polyethylene glycol having an average molecular weight of 300 to 1,000.
  2. 3. A pharmaceutical composition according to claim 1 wherein the solid, water-soluble pharmaceutical carrier is substantially a mixture of lactose and sucrose.
  3. 4. A pharmaceutical composition according to claim 1 in the form of tablets containing 0.1 to 1.0 mg. of nitroglycerin per tablet.
US00149072A 1971-06-01 1971-06-01 Stabilized molded sublingual nitroglycerin tablets Expired - Lifetime US3789119A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14907271A 1971-06-01 1971-06-01

Publications (1)

Publication Number Publication Date
US3789119A true US3789119A (en) 1974-01-29

Family

ID=22528688

Family Applications (1)

Application Number Title Priority Date Filing Date
US00149072A Expired - Lifetime US3789119A (en) 1971-06-01 1971-06-01 Stabilized molded sublingual nitroglycerin tablets

Country Status (5)

Country Link
US (1) US3789119A (en)
BE (1) BE784136A (en)
CA (1) CA983854A (en)
FR (1) FR2140028B1 (en)
GB (1) GB1343374A (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873727A (en) * 1971-06-01 1975-03-25 Parke Davis & Co Stabilization of molded sublingual nitroglycerin tablets
US3885026A (en) * 1972-09-20 1975-05-20 Boehringer Mannheim Gmbh Preparation of porous tablets
US4073931A (en) * 1974-03-27 1978-02-14 Teijin Limited Nitroglycerine inclusion compounds with cyclodextrin and composition containing same
US4091091A (en) * 1973-11-08 1978-05-23 Eli Lilly And Company Stabilized nitroglycerin tablets
US4134943A (en) * 1975-12-16 1979-01-16 Boehringer Mannheim Gmbh Production of porous tablets
WO1983000093A1 (en) * 1981-07-08 1983-01-20 Key Pharma Trinitroglycerol sustained release vehicles and preparation therefrom
US4470962A (en) * 1979-08-14 1984-09-11 Key Pharmaceuticals, Inc. Polymeric diffusion matrix
US4481220A (en) * 1981-03-13 1984-11-06 Sanol Schwarz Gmbh Water-soluble composition for forming an aqueous isotonic nitroglycerine solution and the nitroglycerine solution formed
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4486193A (en) * 1981-07-22 1984-12-04 Alza Corporation Method for treating ischemic conditions by administering drug by two routes
US4562024A (en) * 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
US4654209A (en) * 1979-11-06 1987-03-31 Euroceltique, S.A. Preparation for percutaneous administration
US4704119A (en) * 1983-02-03 1987-11-03 Alza Corporation Method comprising transdermal and buccal treatment of angina
US4812313A (en) * 1981-06-29 1989-03-14 Alza Corporation Method for lessening the incidence of anginal attacks
US4834979A (en) * 1981-06-29 1989-05-30 Alza Corporation Medical bandage for administering beneficial drug
US4846826A (en) * 1981-07-22 1989-07-11 Alza Corporation Method for treating ischemic conditions
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4954344A (en) * 1981-06-29 1990-09-04 Alza Corporation Method for treating nocturnal angina
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US6036974A (en) * 1992-10-02 2000-03-14 Eisai Co. Ltd. Method and apparatus for preparation of molded tablet and thereby prepared molded tablet
US6544557B2 (en) 2001-01-09 2003-04-08 Pan Pharmaceutical Limited Effervescent tablet compositions
CN111517960A (en) * 2020-05-19 2020-08-11 启东市新晨企业管理咨询有限公司 Continuous production nitroglycerin tablet
CN114469881A (en) * 2022-03-14 2022-05-13 河北坤安药业有限公司 Nitroglycerin tablet and preparation method thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296275A1 (en) 2003-07-08 2005-01-21 Nurbey Vladimirovich Gulia Wide-range continuously variable-ratio drive
EP3354259A1 (en) * 2011-02-25 2018-08-01 G. Pohl-Boskamp GmbH & Co. KG Stabilized granules containing glyceryl trinitrate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1541744A (en) * 1924-02-18 1925-06-09 Lilly Co Eli Medicinal tablet
US2540253A (en) * 1949-02-08 1951-02-06 Merck & Co Inc Granulation process
US2648698A (en) * 1949-07-29 1953-08-11 Hercules Powder Co Ltd Desensitized liquid explosives
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3028307A (en) * 1959-05-27 1962-04-03 Warner Lambert Pharmaceutical Pre-dried granulation and production of sublingual compressed organic nitrate tablets with selected solubilizing agents
US3511914A (en) * 1967-01-31 1970-05-12 Schering Corp Throat lozenge vehicle

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1541744A (en) * 1924-02-18 1925-06-09 Lilly Co Eli Medicinal tablet
US2540253A (en) * 1949-02-08 1951-02-06 Merck & Co Inc Granulation process
US2648698A (en) * 1949-07-29 1953-08-11 Hercules Powder Co Ltd Desensitized liquid explosives
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Stephenson et al., J. Pharm. Pharma Col(3): 767 776 (1951) Tablets of Glycoryl Trinitrate *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873727A (en) * 1971-06-01 1975-03-25 Parke Davis & Co Stabilization of molded sublingual nitroglycerin tablets
US3885026A (en) * 1972-09-20 1975-05-20 Boehringer Mannheim Gmbh Preparation of porous tablets
US4091091A (en) * 1973-11-08 1978-05-23 Eli Lilly And Company Stabilized nitroglycerin tablets
US4073931A (en) * 1974-03-27 1978-02-14 Teijin Limited Nitroglycerine inclusion compounds with cyclodextrin and composition containing same
US4134943A (en) * 1975-12-16 1979-01-16 Boehringer Mannheim Gmbh Production of porous tablets
US4470962A (en) * 1979-08-14 1984-09-11 Key Pharmaceuticals, Inc. Polymeric diffusion matrix
US4654209A (en) * 1979-11-06 1987-03-31 Euroceltique, S.A. Preparation for percutaneous administration
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4481220A (en) * 1981-03-13 1984-11-06 Sanol Schwarz Gmbh Water-soluble composition for forming an aqueous isotonic nitroglycerine solution and the nitroglycerine solution formed
US4834979A (en) * 1981-06-29 1989-05-30 Alza Corporation Medical bandage for administering beneficial drug
US4954344A (en) * 1981-06-29 1990-09-04 Alza Corporation Method for treating nocturnal angina
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4812313A (en) * 1981-06-29 1989-03-14 Alza Corporation Method for lessening the incidence of anginal attacks
WO1983000093A1 (en) * 1981-07-08 1983-01-20 Key Pharma Trinitroglycerol sustained release vehicles and preparation therefrom
US4846826A (en) * 1981-07-22 1989-07-11 Alza Corporation Method for treating ischemic conditions
US4486193A (en) * 1981-07-22 1984-12-04 Alza Corporation Method for treating ischemic conditions by administering drug by two routes
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4562024A (en) * 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
US4704119A (en) * 1983-02-03 1987-11-03 Alza Corporation Method comprising transdermal and buccal treatment of angina
US6036974A (en) * 1992-10-02 2000-03-14 Eisai Co. Ltd. Method and apparatus for preparation of molded tablet and thereby prepared molded tablet
US6544557B2 (en) 2001-01-09 2003-04-08 Pan Pharmaceutical Limited Effervescent tablet compositions
CN111517960A (en) * 2020-05-19 2020-08-11 启东市新晨企业管理咨询有限公司 Continuous production nitroglycerin tablet
CN114469881A (en) * 2022-03-14 2022-05-13 河北坤安药业有限公司 Nitroglycerin tablet and preparation method thereof

Also Published As

Publication number Publication date
FR2140028A1 (en) 1973-01-12
DE2226322A1 (en) 1972-12-14
GB1343374A (en) 1974-01-10
DE2226322B2 (en) 1976-04-22
BE784136A (en) 1972-09-18
CA983854A (en) 1976-02-17
FR2140028B1 (en) 1975-06-20

Similar Documents

Publication Publication Date Title
US3789119A (en) Stabilized molded sublingual nitroglycerin tablets
KR930007251B1 (en) Process for preparing stable nicorandil preparation
US4824664A (en) Effervescent couples, histamine H2 -antagonist effervescent compositions containing them and their preparation
US4665081A (en) Solid nifedipine preparations and a process for preparing same
US4198391A (en) Pharmaceutical compositions
IE902216A1 (en) Fast dissolving dosage forms
US3778510A (en) Process for the production of lyophilized liver extract
EP0361680A2 (en) Morphine-containing composition
KR940000232B1 (en) Process for preparing stable nicorandil preparation
JPS599539B2 (en) Nitroglycerin aqueous solution and its manufacturing method
CA2011943A1 (en) Compositions for the preparation of dosage-form active vitamins d3 and process for preparing stable dosage-form active vitamins d3 by using the same
US4906647A (en) Stabilized pharmaceutical compositions
US3873727A (en) Stabilization of molded sublingual nitroglycerin tablets
US3271256A (en) Chloroform in hard candy
US4067960A (en) Pharmaceutical compositions containing cardiac glycoside
JPS6118725A (en) Solid drug preparation containing dihydropyridines
GB2033915A (en) Organopolysiloxane/silica pharmaceutical compositions
JP2532224B2 (en) Nicorandil tablet manufacturing method
IE49243B1 (en) Nabilone granulation
CA1095411A (en) Cardiotonic gelatin capsules
US5266581A (en) Solid composition containing dihydropyridine, PVP and PVPP
CZ149996A3 (en) Pharmaceutical composition, pharmaceutical preparation process of its preparation
KR20010080133A (en) HIGH PURITY COMPOSITION COMPRISING (7α,17α)-17-HYDROXY-7-METHYL-19-NOR-17-PREGN-5(10)-EN-20-YN-3-ONE
JPS63270624A (en) Production of stabilized nicorandil pharmaceutical
IE883032L (en) Pharmaceutical compositions comprising a piperidinoalkanol